See Prescribing Information, including Boxed Warning. Find information for healthcare professionals about once-daily AUSTEDO XR.

See Important Safety Information, including Boxed Warning. How AUSTEDO XR® (deutetrabenazine) extended-release tablets may help.

Aug 20, 2025 · Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more

Dec 8, 2025 · Tardive dyskinesia is a side effect that causes uncontrollable, repetitive body movements. It is caused by long-term use of antipsychotic medications.

Pharmacology Vesicular monoamine transporter 2 (VMAT2) is a protein that regulates the packaging and release of monoamines (dopamine, serotonin, norepinephrine, and histamine). VMAT2 inhibitors …

Deutetrabenazine, sold under the brand name Austedo, is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and tardive …

Nov 7, 2025 · AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting …

Tardive dyskinesia (TD) is a movement disorder that causes a range of repetitive muscle movements in the face, neck, arms, and legs (see side bar). TD symptoms are beyond a person’s control. These …

Sep 21, 2025 · Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine)...

AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea. See safety info including Boxed Warning.